These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18923820)

  • 21. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin.
    Wigger A; Sánchez MM; Mathys KC; Ebner K; Frank E; Liu D; Kresse A; Neumann ID; Holsboer F; Plotsky PM; Landgraf R
    Neuropsychopharmacology; 2004 Jan; 29(1):1-14. PubMed ID: 12942143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
    Griebel G; Simiand J; Serradeil-Le Gal C; Wagnon J; Pascal M; Scatton B; Maffrand JP; Soubrie P
    Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6370-5. PubMed ID: 11959912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The vasopressin-induced excitation of hypoglossal and facial motoneurons in young rats is mediated by V1a but not V1b receptors, and is independent of intracellular calcium signalling.
    Reymond-Marron I; Tribollet E; Raggenbass M
    Eur J Neurosci; 2006 Sep; 24(6):1565-74. PubMed ID: 17004920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of central vasopressin administration to infant rats.
    Winslow JT; Insel TR
    Eur J Pharmacol; 1993 Mar; 233(1):101-7. PubMed ID: 8472738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptor.
    Shoblock JR; Welty N; Nepomuceno D; Lord B; Aluisio L; Fraser I; Motley ST; Sutton SW; Morton K; Galici R; Atack JR; Dvorak L; Swanson DM; Carruthers NI; Dvorak C; Lovenberg TW; Bonaventure P
    Psychopharmacology (Berl); 2010 Feb; 208(2):265-77. PubMed ID: 19953226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors.
    Derick S; Cheng LL; Voirol MJ; Stoev S; Giacomini M; Wo NC; Szeto HH; Ben Mimoun M; Andres M; Gaillard RC; Guillon G; Manning M
    Endocrinology; 2002 Dec; 143(12):4655-64. PubMed ID: 12446593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypothalamic Vasopressinergic Projections Innervate Central Amygdala GABAergic Neurons: Implications for Anxiety and Stress Coping.
    Hernández VS; Hernández OR; Perez de la Mora M; Gómora MJ; Fuxe K; Eiden LE; Zhang L
    Front Neural Circuits; 2016; 10():92. PubMed ID: 27932956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.
    Hiroyama M; Wang S; Aoyagi T; Oikawa R; Sanbe A; Takeo S; Tanoue A
    Eur J Pharmacol; 2007 Mar; 559(2-3):89-97. PubMed ID: 17275806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
    Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
    Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vasopressin(4-9) fragment activates V1a-type vasopressin receptor in rat supraoptic neurones.
    Gouzènes L; Dayanithi G; Moos FC
    Neuroreport; 1999 Jun; 10(8):1735-9. PubMed ID: 10501566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New topics in vasopressin receptors and approach to novel drugs: role of the vasopressin receptor in psychological and cognitive functions.
    Egashira N; Mishima K; Iwasaki K; Oishi R; Fujiwara M
    J Pharmacol Sci; 2009 Jan; 109(1):44-9. PubMed ID: 19151541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior in zebrafish.
    Braida D; Donzelli A; Martucci R; Capurro V; Busnelli M; Chini B; Sala M
    Psychopharmacology (Berl); 2012 Mar; 220(2):319-30. PubMed ID: 21956239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral vector-mediated gene transfer of the vole V1a vasopressin receptor in the rat septum: improved social discrimination and active social behaviour.
    Landgraf R; Frank E; Aldag JM; Neumann ID; Sharer CA; Ren X; Terwilliger EF; Niwa M; Wigger A; Young LJ
    Eur J Neurosci; 2003 Jul; 18(2):403-11. PubMed ID: 12887422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat.
    Mak P; Broussard C; Vacy K; Broadbear JH
    J Psychopharmacol; 2012 Apr; 26(4):532-42. PubMed ID: 21890582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice.
    Egashira N; Tanoue A; Matsuda T; Koushi E; Harada S; Takano Y; Tsujimoto G; Mishima K; Iwasaki K; Fujiwara M
    Behav Brain Res; 2007 Mar; 178(1):123-7. PubMed ID: 17227684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.
    Marir R; Virsolvy A; Wisniewski K; Mion J; Haddou D; Galibert E; Meraihi Z; Desarménien MG; Guillon G
    Br J Pharmacol; 2013 Sep; 170(2):278-92. PubMed ID: 23725319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.
    Iijima M; Yoshimizu T; Shimazaki T; Tokugawa K; Fukumoto K; Kurosu S; Kuwada T; Sekiguchi Y; Chaki S
    Br J Pharmacol; 2014 Jul; 171(14):3511-25. PubMed ID: 24654684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vasopressin V1a, but not V1b, receptors within the PVN of lactating rats mediate maternal care and anxiety-related behaviour.
    Bayerl DS; Hönig JN; Bosch OJ
    Behav Brain Res; 2016 May; 305():18-22. PubMed ID: 26909846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
    J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.